Morse Asset Management’s ADMA Biologics ADMA Stock Holding History

Morse Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$566K	Sell	67,649 -8,745	-11%	-$79.7K	0.09%	127
2026 Q1	$688K	Buy	76,394 +73,964	+3,044%	+$1.17M	0.14%	114
2025 Q4	$44.3K	Buy	+2,430	New	+$41K	0.01%	230
2025 Q3	–	Sell	-44,009	Closed	-$801K	–	370
2025 Q2	$801K	Buy	44,009 +35,309	+406%	+$720K	0.18%	99
2025 Q1	$173K	Buy	8,700 +1,400	+19%	+$24.2K	0.04%	149
2024 Q4	$125K	Buy	7,300 +7,075	+3,144%	+$133K	0.03%	170
2024 Q3	$4.5K	Buy	+225	New	+$3.5K	﹤0.01%	288

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Morse Asset Management's ADMA Position: Q2 2026 in Review

Morse Asset Management reduced its ADMA Biologics (ADMA) stake by 11% in Q2 2026, selling an estimated $79.7K and leaving 67,649 shares worth $566K. The position accounts for 0.09% of the portfolio, ranked #127.

Morse Asset Management first reported a position in ADMA in Q3 2024 and has held it in 7 quarters since. The position peaked at $801K in Q2 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Morse Asset Management held 67,649 shares of ADMA Biologics worth $566K as of Q2 2026.
Morse Asset Management sold 8,745 ADMA Biologics shares in Q2 2026, an estimated $79.7K.
ADMA Biologics made up 0.09% of Morse Asset Management's portfolio in Q2 2026, its #127 holding.
Morse Asset Management first reported a position in ADMA Biologics in Q3 2024 and has held it in 7 quarters since.
Morse Asset Management's ADMA Biologics position peaked at $801K in Q2 2025.
323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Morse Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.